pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

integral-molecular PRESS RELEASE ARCHIVE

Jun 21, 2023

Integral Molecular Awarded $1 Million by Commonwealth of Pennsylvania to Support Biotechnology Pandemic Research Center

May 23, 2023

A Shot in the Arm for Flu Research: Integral Molecular Introduces Off-the-Shelf Reagents to Evaluate 2023/2024 Influenza Vaccine Efficacy

Apr 21, 2023

Integral Molecular Opens New Research Center in Philadelphia Encompassing Pandemic Preparedness Laboratories

Jan 5, 2023

Integral Molecular Reveals Mechanism Underlying Exquisite Specificity of Claudin 6 Therapeutic Antibody Being Developed for Solid Tumors

Oct 20, 2022

Integral Molecular Launches New Product Lines of Safe Reporter Viruses for Vaccine Development and Pandemic Preparedness

Sep 15, 2022

Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies

Sep 7, 2022

FDA Accepts Integral Molecular's Letter of Intent (LOI) on Membrane Proteome Array Antibody Specificity Test Into ISTAND Drug Development Tools Pilot Program

Jun 8, 2022

Integral Molecular and Optimeos Life Sciences Enter Partnership to Develop mRNA and DNA-Based Gene Therapies Using Molecular Targeting

May 24, 2022

Integral Molecular Breaks Ground on New Headquarters, Doubling in Size

Apr 25, 2022

Lonza Early Development Services and Integral Molecular to Offer Complementary Expertise to Enhance Early De-risking of Biotherapeutics

Mar 8, 2022

Integral Molecular Partners with Philadelphia FIGHT Medical Clinic to Support Community Health

Jan 5, 2022

Integral Molecular Adds Transgenic Humanized Mice to Expand its MPS Antibody Discovery Platform Through a Partnership with Alloy Therapeutics

Dec 7, 2021

Integral Molecular Adds Omicron to its Panel of 68 SARS-CoV-2 Reporter Virus Variants to Assess the Effectiveness of Vaccines and Therapeutics

Nov 3, 2021

Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics

Nov 2, 2021

Integral Molecular and Integrated BioTherapeutics Collaborate to Engineer Broadly Protective Ebolavirus Vaccines

Oct 12, 2021

Philadelphia Biotech Integral Molecular Celebrates 20 Years of Innovation, Growth, and Community

Aug 18, 2021

Integral Molecular's Extensive Collection of SARS-CoV-2 Reporter Virus Variants Supports the Clinical Development of Vaccines and MAbs Against Coronavirus

Jul 30, 2021

Integral Molecular Launches Transgene Protein Engineering Platform to Address Challenges in Gene Therapy

Jun 11, 2021

Integral Molecular's Rapid SARS-CoV-2 Epitope Mapping Supports Regulatory Requirements for the Development of Therapeutic Antibodies Effective Against Viral Variants

Jun 8, 2021

Integral Molecular Expands Partnership with Japan's Life Sciences Distributor Funakoshi to Provide Access to Antibody Specificity and Epitope Mapping Services

Apr 8, 2021

Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel Claudin 6 Antibodies for Gynecologic Cancer Therapeutic Program

Feb 5, 2021

Integral Molecular Enables Rapid Resistance Testing of Vaccines and Drugs Against Emerging Coronavirus Variants

Jan 7, 2021

Integral Molecular and Optimeos Partner to Deliver Long-acting Therapeutic Antibodies Using Nanoparticle Formulation Technology

Nov 24, 2020

Integral Molecular Announces Best-in-Class Antibodies Against Complex Oncology Target Claudin 18.2

Nov 19, 2020

Integral Molecular Partners with China's Leading Preclinical CRO JOINN for Comprehensive Specificity Testing of Antibodies and CAR-T Therapeutics

Oct 14, 2020

Totient Leverages Integral Molecular's Membrane Proteome Array to Advance Cancer Therapeutic Discovery

Sep 21, 2020

Integral Molecular Awarded Grant from the Commonwealth of Pennsylvania to Advance COVID-19 Research

Sep 10, 2020

Humanized Chicken Antibody Technology to Drive Next Generation of Integral Molecular's MPS Antibody Discovery Platform

Jul 14, 2020

Integral Molecular Expands its Reporter Virus Technology to Enable Broad Testing for Coronavirus Protection Against Emerging Strains Including D614G

Jun 12, 2020

Integral Molecular Provides Rapid Safety Testing of COVID-19 Antibody Therapeutics with its Membrane Proteome Array Technology

Apr 30, 2020

Integral Molecular Develops Test for Neutralizing Antibodies in COVID-19 Patients and Clinical Trials

Apr 23, 2020

Integral Molecular Receives NIAID Award to Combat COVID-19

Mar 9, 2020

Integral Molecular Accelerates Coronavirus Vaccine Research

Feb 13, 2020

Integral Molecular Launches ReadyMap Services for Rapid, Conformational Epitope Mapping

Jan 9, 2020

Integral Molecular Announces Preclinical P2X7 Antibody Assets for Autoimmune Disorders

Nov 14, 2019

Integral Molecular to Advance Vaccine Discovery with NIH Contract for $5.5M

Oct 18, 2019

Philadelphia's Integral Molecular Opens New Research Center in Response to Upsurge in Antibody Discovery Partnerships

Sep 26, 2019

Integral Molecular Selected as the First Industry Partner in The Wistar Institute's Biomedical Research Technician Apprenticeship

Jun 26, 2019

Integral Molecular Presents Data on Monoclonal Antibodies (MAbs) Against SLC2A4 (GLUT4), a Critical Target for Diabetes

May 28, 2019

Integral Molecular Reaches Milestone in Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo

Apr 16, 2019

Integral Molecular Doubles Antibody Characterization Capacity Within Philadelphia's Science Center

Mar 26, 2019

Integral Molecular to Present Claudin 6 MAbs, a Therapeutic Asset for Solid Tumors, at Annual AACR Conference

Jan 7, 2019

Integral Molecular Enters Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo

Jan 3, 2019

Integral Molecular Announces Antibody Discovery Collaboration with Ono Pharmaceutical

Dec 4, 2018

Integral Molecular's Therapeutic MAbs Against CB1 to Treat NASH Enter New Development Phase Following $1.4M NIH Award

Nov 1, 2018

Integral Molecular Awarded NIH Grant to Discover Neuroimmune Drug Targets in Alzheimer’s Disease

May 30, 2018

Integral Molecular’s MPS Antibody Discovery Platform Yields Therapeutic Assets for Oncology and Metabolic Syndrome

Mar 13, 2018

Integral Molecular’s Protein Engineering Technology Facilitates HIV Vaccine Development

Sep 21, 2016

Integral Molecular launches target specificity technology to improve safety of biotherapeutics

Google Analytics Alternative